Our services We perform state of the art preclinical and clinical research studies in respiratory infections and airway diseases... Find out more
Our team Virtus’s Founders have worked together since 2001 in various academic and commercial settings. Professor Sebastian Johnston Director & Chief Medical Officer Dr Michael R Edwards Managing & Scientific Director Meet the full team
Infection rate The overall infection rate of our current stock of rhinovirus is 82% in asthmatics, COPD and healthy volunteers. Source : Deloitte 2015
Get in touch Want to find out more how we can help you develop the next block-buster medicine in asthma or COPD? Get in touch. I agree to the Virtus Privacy Policy Submit your request
Our Vision We perform state of the art preclinical and clinical research studies in respiratory infections and airway diseases... Learn more
Keep Updated With Our Progress Aceri officto dolorem quis quaeces. Volupit idi ulpariorror moleser iorempores est, volores endenda nimusda voluptam ius. I agree to the Virtus Privacy Policy The email address is incorrect Please agree to our Privacy and Policy Something went wrong Subscribe to newsletter